CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Marizyme Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Marizyme Inc
555 HERITAGE DRIVE, SUITE 205
Phone: (561) 935-9955p:561 935-9955 JUPITER, FL  33458  United States Ticker: MRZMMRZM

Business Summary
Marizyme, Inc. is a multi-technology life science company. The Company is engaged in the development and commercialization of medical technologies that improves patient health outcomes. Its products include DuraGraft, MATLOC 1 and Krillase. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. MATLOC is a lab-on-chip digital screening and diagnostic device platform, which is being developed for quantitative chronic kidney disease (CKD) assessment. Krillase can be used in the treatment of chronic wounds and burns, and other clinical applications. Its DuraGraft is an endothelial damage inhibitor (EDI), indicated for cardiac bypass, peripheral bypass, and other vascular surgeries.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Vithalbhai D.Dhaduk 69 11/16/2021 2/22/2021
Chief Executive Officer, Secretary, Director DavidBarthel 65 10/1/2022 11/10/2021
Chief Financial Officer, Treasurer GeorgeKovalyov 38 12/1/2021 12/1/2021
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
GBS Software AG Am Storrenacker 1a KARLSRUHE Germany
Somahlution, Inc. 225 Chimney Corner Lane Jupiter FL United States

Business Names
Business Name
GBS Enterprises Inc
GBSX
GBSXD
11 additional Business Names available in full report.

General Information
Number of Employees: 13 (As of 3/24/2023)
Outstanding Shares: 46,666,760 (As of 11/14/2023)
Shareholders: 385
Stock Exchange: OTC
Federal Tax Id: 273755055
Fax Number: (770) 720-1335


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024